Navigation Links
Valeritas Announces Appointment of New CEO
Date:6/1/2009

Former Johnson & Johnson Senior Executive Kristine Peterson to Take Helm

PARSIPPANY, N.J., June 1 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired Kristine Peterson to serve as its Chief Executive Officer.

Peterson brings 26 years of industry experience to Valeritas, with her most recent successes as Company Group Chair of Johnson & Johnson's Biotech Business where she was directly responsible for commercial, research & development and supply chain/manufacturing for biotech, oncology, immunology, and cell therapy.

"We are thrilled that Kris has joined the Valeritas executive team," said Vaughn Kailian, Executive Chairman of the Board, Valeritas, Inc and Managing Director of MPM Capital. "She exhibits a broad range of experience and leadership qualities, along with a deep compassion for patients and their challenges. This exceptional skill set makes her the ideal leader to take Valeritas to the next level as a fully operational medical technology company."

"Joining Valeritas at this pivotal time in its lifecycle is a great privilege," said Peterson. "With the company's strong financial backing, a potentially life changing first product, and a broad technology platform that can support a wide array of therapeutic options, Valeritas is positioned to be a highly successful company."

Peterson joined Johnson & Johnson in August 2004 as Executive Vice President, Pharmaceutical Group Strategic Marketing with responsibility for developing global launch plans for Internal Medicine, Metabolics, Central Nervous System, Oncology, Virology, Anemia and Pain franchises. Prior to joining J&J, Peterson was Senior Vice President, Commercial Operations, Biovail Corporation and President Biovail Pharmaceuticals. In this role, she was resp
'/>"/>

SOURCE Valeritas, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
2. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
3. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... stock held by American Red Cross, in a ... in PRDT to 77%, - American Red Cross to ... MONTREAL and CAMBRIDGE, England, April 9 /PRNewswire-FirstCall/ -,ProMetic ... a Letter of Intent ("LOI") to acquire the American ...
... April 9 Francis S. Collins, M.D., ... Genome Project, has been named,recipient of the ... Center for Ethics and Excellence at Case ... ), The Inamori Ethics Prize honors ...
... Genetic Engineering,and Biotechnology News (GEN), http://www.genengnews.com ... on New Polymeric Drug Delivery Systems, on,Thursday, April ... is institute professor, chemical and biomedical engineering,Massachusetts Institute ... innovator in modern drug delivery," says John Sterling,Editor-in-Chief ...
Cached Biology Technology:ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 7Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems 2
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... (Tuesday, April 1, 2008) Identifying genes that ... mouse used to be a monumental task. New ... effective for even the smallest laboratories. This months ... www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for screening the mouse ...
... be the cruelest month? , ... reminiscent of 1993 and 1994, back-to-back years of serious flooding, with ... damage, damaging and destroying more than 50,000 homes and killing at ... Parallels this year include abnormally high levels of precipitation ...
... Like sentinels at their posts, an array of buoys ... on duty in the Stellwagen Bank National Marine Sanctuary ... months, recording sounds from whales, fish, ships and other ... will analyze the biological sounds to help develop a ...
Cached Biology News:Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2Geologist decries floodplain development 2Geologist decries floodplain development 3Researchers to develop ocean sanctuary 'noise budget' to evaluate potential impact on marine mammals 2Researchers to develop ocean sanctuary 'noise budget' to evaluate potential impact on marine mammals 3
... Reagent A - Fixation medium Reagent B ... intended for fixing cells in suspension with ... with Reagent B. This procedure gives antibodies ... morphological scatter characteristics of the cells intact. ...
... polyclonal to JNK1 (phospho T183 + Y185) ... domain containing phosphorylated T183/Y185. Reactivity / Specificity ... yet tested in other species. Background Information ... the ERK, JNK, and p38 kinases. The members ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
... been designed to provide a thin film-like barrier when ... slide. This barrier creates the proper surface tension ... on the slide. PAP Pen contains a special ... It can be removed, if desired, by xylene after ...
Biology Products: